Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial
Main Authors: | Ji Sung Lee, Jinseok Kim, Byeong-zu Ghang, Jihye Choi, Bin Yoo |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-06-01
|
Series: | RMD Open |
Online Access: | https://rmdopen.bmj.com/content/8/2/e001944.full |
Similar Items
-
Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol
by: Ajinkya Pawar, et al.
Published: (2021-04-01) -
Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System
by: Yang Bai, et al.
Published: (2023-09-01) -
Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
by: Xudong Guan, et al.
Published: (2022-09-01) -
The potential renoprotection of xanthine oxidase inhibitors: Febuxostat versus allopurinol
by: Dong-Ryeol Ryu
Published: (2017-09-01) -
A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout
by: Joondon Lee, et al.
Published: (2023-05-01)